Exozymes (EXOZ) Liabilities and Shareholders Equity (2023 - 2026)
Exozymes (EXOZ) posted quarterly Liabilities and Shareholders Equity of $6.0 million for Q4 2025, down 54.19% year-over-year from $13.0 million in Q4 2024, and down 22.64% quarter-over-quarter from $7.7 million in Q3 2025.
Exozymes (EXOZ) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $6.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 54.19% year-over-year to $6.0 million; the TTM figure through Dec 2025 stood at $34.9 million (up 110.27% YoY), while the FY2025 annual figure was $6.0 million, down 54.19% from the prior year.
- Liabilities and Shareholders Equity retreated to $6.0 million in Q4 2025 per EXOZ's latest filing, from $7.7 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $13.0 million in Q4 2024 and bottomed at $3.6 million in Q4 2023.
- Historically, Liabilities and Shareholders Equity has averaged $7.9 million across 3 years, with a median of $7.7 million in 2025.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity jumped 266.29% — and 2025, when it slumped 54.19%.
- Exozymes' Liabilities and Shareholders Equity stood at $3.6 million in 2023, then surged by 266.29% to $13.0 million in 2024, then plunged by 54.19% to $6.0 million in 2025.
- Business Quant data shows EXOZ's Liabilities and Shareholders Equity at $6.0 million in Q4 2025, $7.7 million in Q3 2025, and $9.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | 7.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.98 Mn |
| Dec 31, 2025 | 5.97 Mn |
| Sep 30, 2025 | 7.72 Mn |
| Jun 30, 2025 | 9.68 Mn |
| Mar 31, 2025 | 11.53 Mn |
| Dec 31, 2024 | 13.03 Mn |
| Sep 30, 2024 | 3.56 Mn |
| Dec 31, 2023 | 3.56 Mn |